002898 Share Price Performance
CN¥14.18
2.89 (25.60%)
Price CN¥14.18
Share PriceCN¥14.18
Subdued Growth No Barrier To Sailong Pharmaceutical Group Co.,Ltd.'s (SZSE:002898) Price
Mar 19
Sailong Pharmaceutical Group Co.,Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
002898 Community Narratives
There are no narratives available yet.
Recent 002898 News & Updates
Sailong Pharmaceutical Group Co.,Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
- Earnings per share (EPS)
- -0.28
- Gross Margin
- 22.68%
- Net Profit Margin
- -20.45%
- Debt/Equity Ratio
- 32.1%
Sailong Pharmaceutical Group Co.,Ltd. Competitors
Snowflake Analysis
About 002898
- Founded
- 2002
- Employees
- 514
- CEO
- WebsiteView website
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.3%
- 1 Year: 24.1%
- Year to Date: 26.2%
The Industrials sector has led the market, which has gained 1.8%. The market is up 24% over the last 12 months. Looking forward, earnings are forecast to grow by 27% annually. Market details ›